An Open Label, Phase 1 Study of SC‑004 in Subjects With Advanced Solid Tumors

Trial Profile

An Open Label, Phase 1 Study of SC‑004 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs SC 004 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors AbbVie
  • Most Recent Events

    • 18 Jul 2017 Planned number of patients changed from 134 to 108.
    • 18 Jul 2017 Planned End Date changed from 17 May 2021 to 15 Jun 2021.
    • 18 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top